I think the 202 study would be a nice added bit of evidence as the drug is aimed to target early onset symptoms, and even earlier than the 201 study group, so maybe 201 studies are enough, time will tell.
Given that people are being diagnosed and dying at present, as Dr stamler advised they would like to see the drug on the market as soon as possible.
So readers interpretation of Q4 FDA meeting and understanding obviously differ, again time will tell, we have a drug that works, shows statistical improvement with improved biomarkers.
ATH Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)